Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?

SIMPLE SUMMARY: Currently, a combination therapy of standard androgen deprivation therapy (ADT) plus docetaxel or androgen receptor-axis-targeted therapy is the gold standard for metastatic hormone-sensitive prostate cancer (mHSPC) treatment. Compared to ADT monotherapy, combination treatment prolon...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Christian, Baunacke, Martin, Erb, Holger H. H., Füssel, Susanne, Erdmann, Kati, Putz, Juliane, Borkowetz, Angelika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750314/
https://www.ncbi.nlm.nih.gov/pubmed/35008172
http://dx.doi.org/10.3390/cancers14010008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750314/
https://www.ncbi.nlm.nih.gov/pubmed/35008172
http://dx.doi.org/10.3390/cancers14010008

Ejemplares similares